Official websites use. Share sensitive information only on official, secure websites. Assessments included: general physical examination, CADESI lesion scoring, overall clinical response, evaluation of adverse events AEs , body weight and clinical pathology hematology, clinical chemistry and urinalysis.
Owner assessments, including pruritus visual analogue scale, VAS and overall assessment of response were conducted every 3β4 days, either during visits to the clinic or at home. Owners reported AEs to the investigator throughout the study.
No dogs died or stopped treatment due to an AE. The most commonly reported AEs in the cyclosporine A group were associated with the digestive tract, whilst systemic disorders were reported more frequently observed following concurrent therapy. Evaluation of body weight change and clinical pathology indices showed no overall clinically significant abnormalities. In dogs with atopic dermatitis, a short initiating course of prednisolone expedited the efficacy of cyclosporine A in resolving pruritus and associated clinical signs.
The observed adverse events were consistent with those expected for the individual veterinary medicinal products. Atopic dermatitis, a common skin disease of dogs, is defined as a genetically predisposed inflammatory and pruritic skin disease with characteristic clinical features associated with IgE antibodies, usually directed against environmental allergens [ 1 , 2 ]. The chronic form of the disease is characterised by pruritus with or without recurrent skin or ear infections.
Primary skin lesions usually consist of erythematous macules, patches and small papules. Most patients, however, present with lesions that occur secondary to self-trauma, including self-induced alopecia, lichenification and hyperpigmentation.
